Defining the Mycobiome in Bladder Cancer

Affiliations

Editorial

Benjamin D Mercier et al. Eur Urol Open Sci. 2022.

. 2022 Dec 27:48:70-71.

doi: 10.1016/j.euros.2022.11.023. eCollection 2023 Feb.

¹ Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.

No abstract available

Comment on

Human Gut Mycobiome and Fungal Community Interaction: The Unknown Musketeer in the Chemotherapy Response Status in Bladder Cancer.
Bukavina L, Prunty M, Isali I, Calaway A, Ginwala R, Sindhani M, Ghannoum M, Mishra K, Kutikov A, Uzzo RG, Ponsky LE, Abbosh PH. Bukavina L, et al. Eur Urol Open Sci. 2022 Jul 12;43:5-13. doi: 10.1016/j.euros.2022.06.005. eCollection 2022 Sep. Eur Urol Open Sci. 2022. PMID: 36353067 Free PMC article.

1. Redelman-Sidi G., Glickman M.S., Bochner B.H. The mechanism of action of BCG therapy for bladder cancer—a current perspective. Nat Rev Urol. 2014;11:153–162. doi: 10.1038/nrurol.2014.15. - DOI - PubMed
1. Aso Y., Akaza H., Kotake T., Tsukamoto T., Imai K., Naito S. Preventive effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer in a double-blind trial. The BLP Study Group. Eur Urol. 1995;27:104–109. doi: 10.1159/000475138. - DOI - PubMed
1. Lloyd-Price J., Mahurkar A., Rahnavard G., et al. Strains, functions and dynamics in the expanded Human Microbiome Project. Nature. 2017;550:61–66. doi: 10.1038/nature23889. - DOI - PMC - PubMed
1. Sepich-Poore G.D., Zitvogel L., Straussman R., Hasty J., Wargo J.A., Knight R. The microbiome and human cancer. Science. 2021;371:eabc4552. doi: 10.1126/science.abc4552. - DOI - PMC - PubMed
1. Davar D., Dzutsev A.K., McCulloch J.A., et al. Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients. Science. 2021;371:595–602. doi: 10.1126/science.abf3363. - DOI - PMC - PubMed